Allergies & Asthma

Now that my son, Morgan, is a 25 year old man he is making the informed decisions about all aspects of life, including choosing allergists, physicians and whether to receive a COVID vaccine. I feel secure in the knowledge that he is fully capable of making these decisions, and it’s really wonderful that he and

Now that my son, Morgan, is a 25 year old man he is making the informed decisions about all aspects of life, including choosing allergists, physicians and whether to receive a COVID vaccine. I feel secure in the knowledge that he is fully capable of making these decisions, and it’s really wonderful that he and

Among children with uncontrolled, moderate-to-severe asthma, treatment with the biologic dupilumab (Dupixent) was associated with a reduction in exacerbation and improvements in lung function in phase III findings from the international VOYAGE trial. Evidence of lung function improvement occurred within 2 weeks of treatment initiation, and was sustained during the 52-week randomized, placebo-controlled trial. Compared

Among children with uncontrolled, moderate-to-severe asthma, treatment with the biologic dupilumab (Dupixent) was associated with a reduction in exacerbation and improvements in lung function in phase III findings from the international VOYAGE trial. Evidence of lung function improvement occurred within 2 weeks of treatment initiation, and was sustained during the 52-week randomized, placebo-controlled trial. Compared

I was diagnosed with MCAS (Mast Cell Activation Syndrome) almost 10 years ago. It took a few years of trying every prescription medication my GI doctor could find to begin to get my symptoms stabilized, and even then I still was suffering from weight loss, fatigue, stomach pain, insomnia and an inability to increase my

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted daily, but keeping up can be a challenge. As an aid for our readers and for a little amusement, here is a 10-question quiz based on the news of the

A first-in-class drug under development for severe asthma passed what its developers hope is the final test: achieving its primary endpoint in a phase III registration trial dubbed NAVIGATOR and now reported in a major journal. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), cut the annualized rate of asthma exacerbations by more than

A novel gene therapy for severe combined immunodeficiency from adenosine deaminase deficiency (ADA-SCID) restored immune cell counts without death or need for enzyme replacement therapy, researchers reported. Survival without needing to re-initiate pegylated ADA enzyme replacement therapy, or have a rescue allogeneic hematopoietic stem cell transplantation (AHCT), was 95% to 97% at last follow-up at

A novel gene therapy for severe combined immunodeficiency from adenosine deaminase deficiency (ADA-SCID) restored immune cell counts without death or need for enzyme replacement therapy, researchers reported. Survival without needing to re-initiate pegylated ADA enzyme replacement therapy, or have a rescue allogeneic hematopoietic stem cell transplantation (AHCT), was 95% to 97% at last follow-up at

You might think that when asthma patients were switched involuntarily from regular insurance to high-deductible health plans (HDHPs), a substantial number would cut corners on their daily controller medications — but you would mostly be wrong, researchers said. In fact, in a study of some 185,000 pediatric and adult patients with asthma spanning 2002 to